These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 37982631

  • 1. In vitro activity of ceftazidime-avibactam, imipenem-relebactam, aztreonam-avibactam, and comparators toward carbapenem-resistant and hypervirulent Klebsiella pneumoniae isolates.
    Li D, Yu H, Huang X, Long S, Zhang J.
    Microbiol Spectr; 2023 Dec 12; 11(6):e0280623. PubMed ID: 37982631
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing Klebsiella pneumoniae.
    Zhang W, Guo Y, Li J, Zhang Y, Yang Y, Dong D, Zhu D, He P, Hu F.
    Antimicrob Resist Infect Control; 2018 Dec 12; 7():142. PubMed ID: 30479755
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. New options for bloodstream infections caused by colistin- or ceftazidime/avibactam-resistant Klebsiella pneumoniae.
    Yu W, Luo Q, Shen P, Chen Y, Xu H, Xiao Y, Qiu Y.
    Int J Antimicrob Agents; 2021 Dec 12; 58(6):106458. PubMed ID: 34706255
    [Abstract] [Full Text] [Related]

  • 7. Development of Resistance to Eravacycline by Klebsiella pneumoniae and Collateral Sensitivity-Guided Design of Combination Therapies.
    Xu C, Wei X, Jin Y, Bai F, Cheng Z, Chen S, Pan X, Wu W.
    Microbiol Spectr; 2022 Oct 26; 10(5):e0139022. PubMed ID: 35972286
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Epidemiology and Genomic Characteristics of Bloodstream Infection Caused by Carbapenem-Resistant Klebsiella pneumoniae With Decreased Susceptibility to Aztreonam/Avibactam in China.
    Yu W, Shen P, Chen Y, Zhou K, Chi X, Xiao Y.
    Front Cell Infect Microbiol; 2022 Oct 26; 12():926209. PubMed ID: 35811669
    [Abstract] [Full Text] [Related]

  • 11. Activity of Imipenem-Relebactam and Comparator Agents against Genetically Characterized Isolates of Carbapenem-Resistant Enterobacteriaceae.
    Canver MC, Satlin MJ, Westblade LF, Kreiswirth BN, Chen L, Robertson A, Fauntleroy K, La Spina M, Callan K, Jenkins SG.
    Antimicrob Agents Chemother; 2019 Sep 26; 63(9):. PubMed ID: 31262761
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Carbapenem antibiotic stress increases blaKPC -2 gene relative copy number and bacterial resistance levels of Klebsiella pneumoniae.
    Chen H, Li N, Wang F, Wang L, Liang W.
    J Clin Lab Anal; 2022 Jul 26; 36(7):e24519. PubMed ID: 35718993
    [Abstract] [Full Text] [Related]

  • 16. Ceftazidime-avibactam alone or in combination with Aztreonam versus Polymyxins in the management of carbapenem-Resistant Klebsiella pneumoniae nosocomial Infections (CAPRI study): a retrospective cohort study from South India.
    Sree RA, Gupta A, Gupta N, Veturi S, Reddy LSK, Begum M, Shravani E, Challa HR, Reddy SS, Singamsetty A, Arumilli M, Reddy PN, Tirlangi PK.
    Infection; 2024 Apr 26; 52(2):429-437. PubMed ID: 37697224
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.